Community Research and Development Information Service - CORDIS

H2020

NoCanTher Report Summary

Project ID: 685795
Funded under: H2020-EU.2.1.2.

Periodic Reporting for period 1 - NoCanTher (Nanomedicine upscaling for early clinical phases of multimodal cancer therapy)

Reporting period: 2016-04-01 to 2017-09-30

Summary of the context and overall objectives of the project

The NoCanTher consortium plans to test in humans a new therapy for pancreatic cancer based on magnetic nanoparticles. The disease addressed in this project has a very bad prognosis, particularly, the survival rate after 5 years (< 5%) has not changed over the last 30 years, despite tremendous efforts at the preclinical and clinical stage. Worldwide in 2012 there were 338,000 new cases of pancreatic cancer and 331,000 associated deaths. Currently, surgery is the one curative treatment for PDAC but only a minority of patients present with potentially operable disease (10–20%). Therefore, there is an urgent need to develop effective treatments for this disease, and those based on nanotechnology might solve some of the problems faced with this disease.
Our approach is based on magnetic hyperthermia, where magnetic nanoparticles placed in the tumor are exposed to an alternating magnetic field (AMF) leading to an increase of the temperature of the particles and therefore the tumoral area. This process is able to induce the death of the tumoral cells mainly.
Thus, to test this approach in humans, we need to scale-up the production of magnetic nanoparticles under GMP, certify the medical devices (nanoparticles and AMF generator) and get the approval for the agencies to run the clinical study.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During this period the consortium has been focused in the production and assessment of nanoparticles, preparation of the production line for GMP production and preparation of clinical and preclinical AMF generators.

NoCanTher has been represented at multiple events across Europe, communicating and disseminating the result and aims of the project, reaching out to the general public, researchers, clinicians and stakeholders. An excellent example of this was the consortium’s strong participation in NanoWorld Cancer Day (2nd February 2017), 15 countries united in providing information about smart nanotechnology solutions to beat cancer. We were highly visible across the day with key participations of IMDEA, BIOPRAXIS, VHIR and TCD in the events in Spain and Ireland.

The Spanish event was hosted at Vall D’Hebron Institute of Oncology -one of the NoCanTher partners, and featured three speakers from the consortium. The event was well attended both by the national press and members of the public, giving the NoCanTher project an excellent opportunity to reach a large and varied audience.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

This approach is quite novel and the combination of the two medical devices developed in the consortium have not been employed for the treatment of pancreatic cancer. The challenges ahead are diverse, but we expect to report an effective therapy against pancreatic cancer that can be implemented in hospitals at a moderate cost. Thus, we hope that citizens along Europe will benefit from this innovative therapeutic approach, improving the survival rate and reducing the pain associated with the disease.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top